Thyroid and other Endocrine System Cancers

Anus, Breast, Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Other Digestive Organ, Pancreas, Phase I, Rectum, Small Intestine, Stomach, ThyroidAn Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors
Breast, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Urinary, Phase I, ThyroidFirst-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors
Other Endocrine System, Phase IA Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Other Endocrine SystemA Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
Breast, Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Phase I, Rectum, Stomach, ThyroidA Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors